Itraconazole.

Article Details

Citation Copy to clipboard

Pierard GE, Arrese JE, Pierard-Franchimont C

Itraconazole.

Expert Opin Pharmacother. 2000 Jan;1(2):287-304. doi: 10.1517/14656566.1.2.287 .

PubMed ID

11249550 [ View in PubMed

]

Abstract

Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial fungal infections including difficult-to-treat dermatophytoses and onychomycoses. Furthermore, shortened treatment regimens have proven to be effective, ranging from 1-day treatment for vaginal candidosis to 1-week pulse therapy per month, for 2-4 months, in onychomycosis and follicular dermatophytosis. Clinical experience with itraconazole in the treatment of deep mycoses is less comprehensive. However, results in systemic candidosis, sporotrichosis, blastomycosis, paracoccidioiodomycosis, certain types of histoplasmosis and aspergillosis are extremely encouraging. Itraconazole is less effective in the treatment of chromomycosis and coccidioidomycosis. Nevertheless, considering the refractory nature of these diseases, itraconazole has proven to be a valuable addition to the antifungal drugs currently available for treatment. Itraconazole has been well-tolerated with doses of up to 400 mg/day being generally free of serious adverse effects. However, a potential for drug interactions exists, mediated through the cytochrome P450 enzyme 3A4 system, which should be considered when itraconazole is used as part of a multi-drug regimen.

DrugBank Data that Cites this Article

Drugs

Itraconazole

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Itraconazole	Lanosterol 14-alpha demethylase	Protein	Candida tropicalis	Yes	Inhibitor	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software